MRSN

Mersana Therapeutics, Inc. (MRSN) | Rumor.io

Mersana Therapeutics

MRSN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MRSN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jan 6

Mersana Therapeutics (MRSN) is set to delist from Nasdaq after a merger notice, with a trading suspension requested for January 5, 2026.
The company has completed a merger with Day One Biopharmaceuticals, subject to FDA approval, and has initiated a voluntary delisting process.
The merger has triggered a regulatory filing, starting the review clock for potential approval, and is expected to lead to a major volume spike in the stock.

Generated by AI

Sentiment

Of the messages about MRSN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.64% +4.31
Bearish	—	—	—	12.36% -4.31

Bullish· Nov 13

Mersana Therapeutics ($MRSN) has been acquired by Day One Biopharmaceuticals ($DAWN) for $25 per share in cash, with potential CVR payments bringing the total value to $55.25 per share.
The acquisition is expected to strengthen Day One's oncology pipeline, and the deal is valued at up to $285 million.
Mersana's stock has surged 210% on the news, with some analysts viewing the deal as a bullish sign for the company's future prospects.

Bearish· Jan 10

Mersana Therapeutics' stock drop was attributed to a disappointing outcome in the UPLIFT trial.
The company's strategic restructuring is expected to extend its cash runway.
The stock has been heavily shorted, with some investors warning of potential naked shorts and a possible drop below yesterday's price.

Generated by AI

Topics

Of the messages about MRSN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	4.72%
Announcements	—	100%	100%	82.6%
Controversies	—	0%	0%	0.65%
Earnings	—	0%	0%	1.63%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	10.41%

Analysts· Jul 20

Mersana Therapeutics' $MRSN was downgraded from Outperform to Market Perform at Leerink with a new price target of $13.
Leerink Partners cut $MRSN to market perform with a price target of $55.
Mersana Therapeutics' $MRSN was reiterated as a Buy at HC Wainwright with a price target of $16.

Announcements· Nov 13

Mersana Therapeutics, Inc. (MRSN) has agreed to merge with Day One Biopharmaceuticals (DAWN) in a deal worth up to $285 million.
The deal involves an upfront payment of $25.00 per share in cash, plus up to $30.25 per share in contingent value rights (CVRs) based on clinical, regulatory, and commercial milestones.
The acquisition is expected to strengthen Day One's oncology pipeline, with the transaction expected to close by January 2026.

Technical Analysis· Aug 9

$MRSN has formed a bull flag and is expected to reach $8+ with patience.
The stock's 20 EMA on the 5-minute chart is a key level to watch for a potential NHDO break.
A break above the VWAP at $7 on the 5-minute chart could lead to a high of day for $MRSN.

Generated by AI

Community

Of the messages about MRSN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	39.28%
Newcomers	—	100%	100%	60.72%

Regulars· Nov 13

The deal value when including the CVR is approximately $285M, with a potential worth of $129M at closing.
The acquisition price is $25 per share in cash, with the possibility of up to $30.25 per share in contingent value rights (CVRs).
The deal is a 200% premium, with Mersana's stock price increasing by 204% following the announcement of the acquisition by Day One Biopharmaceuticals.

Newcomers· Nov 13

$MRSN's stock price surged 207.78% after Day One Biopharmaceuticals announced a merger agreement to acquire Mersana Therapeutics for $25 per share in cash, with potential additional payments up to $30.25 per share based on clinical and regulatory milestones.
Newcomers to the market are focused on the potential upside of the merger, with one user noting that the company's management had their options re-priced last Friday, suggesting that the deal may be part of a larger agreement.
The acquisition is seen as a relatively cheap deal, with one user estimating that Day One Biopharmaceuticals is paying around $60-70 million to acquire Mersana, considering the company's cash reserves and the low valuation of the milestones.

Generated by AI

Also Discussed

Investors talking about MRSN also mention

#	Name	Attention
1	GBIO - Generation Bio Co.	——
2	SLRN - Acelyrin, Inc.	——
3	ARAV - Aravive, Inc.	——
4	BioAtla Inc.BCAB	0%new
5	APLS - Apellis Pharmaceuticals, Inc.	——
6	APLT - Applied Therapeutics, Inc.	——
7	ETNB - 89bio, Inc.	——
8	VRNA - Verona Pharma plc	——
9	DCPH - Deciphera Pharmaceuticals, Inc.	——
10	THRX - Theseus Pharmaceuticals, Inc.	——